CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

SOPHiA GENETICS Presents 25% Revenue Growth in Q3 2026

By Public Technologies
  • SOPHiA GENETICS reported third-quarter 2026 revenue of USD 24.27 million, up 25% year over year, in an investor presentation.
  • Adjusted EBITDA loss narrowed to USD 6.07 million from USD 8.84 million a year earlier.
  • Analysis volume rose 19% to a record 118,000; net dollar retention reached 118%.
  • US revenue grew 41%; liquid biopsy revenue more than doubled.
  • A multiyear AstraZeneca agreement covers two companion diagnostic programs targeting solid tumors and blood cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sophia Genetics SA published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk